ClinicalTrials.gg

Program

tapinarof

Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.

Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.

Furthest: phase 4, since Dec 26, 202225 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon121 open or runningphase 4since Dec 26, 2022May 16, 2019Aug 2027phase 3 · NCT07265479
GlaxoSmithKline80 open or runningphase 3since Jun 27, 2017Oct 31, 2013none ahead
Welichem Biotech30 open or runningphase 2since Feb 3, 2009Feb 3, 2009none ahead
Sun Pharmaceutical Industries10 open or runningphase 1since Apr 15, 2026Apr 15, 2026none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Dec 16, 2024Dec 16, 2024none ahead

Also a collaborator on its studies: teva-pharmaceuticals-inc, iqvia-biotech, ppd-development-lp, q2-solutions and icardiac-technologies-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Feb 3, 2009.

  1. Jun 27, 2017Phase 1 study in PsoriasisGlaxoSmithKline · NCT03201978
  2. May 16, 2019Organon's first study: phase 3 study in PsoriasisNew to OrganonOrganon · NCT03956355 · 510 enrolled · United States, Canada
  3. Jun 10, 2019Phase 3 study in PsoriasisOrganon · NCT03983980 · 515 enrolled · United States, Canada
  4. Jul 23, 2019Phase 3 study in PsoriasisOrganon · NCT04053387 · 763 enrolled · United States, Canada
  5. Jul 24, 2019Phase 2 study in Plaque PsoriasisOrganon · NCT04042103 · 21 enrolled · United States
  6. Aug 16, 20212 phase 3 studies in Dermatitis, AtopicOrganon · NCT05014568, NCT05032859
  7. Oct 28, 20212 phase 3 studiesOrganon · NCT05172726, NCT05142774
  8. Nov 8, 2021Phase 2 study in Dermatitis, AtopicOrganon · NCT05186805 · 36 enrolled · United States, Canada
  9. Dec 26, 2022Phase 4 study in PsoriasisOrganon · NCT05680740 · 34 enrolled · United States
  10. Mar 14, 2023Phase 4 study in PsoriasisOrganon · NCT05789576 · 31 enrolled · United States
  11. Dec 16, 2024Teva Pharmaceutical Industries's first study: phase 3 study in Skin DiseasesNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06742957 · 560 enrolled · United States
  12. Nov 21, 2025Phase 3 study in Dermatitis, AtopicOrganon · NCT07265479 · 187 enrolled · United States, Canada
  13. Apr 15, 2026Sun Pharmaceutical Industries's first study: phase 1 study in Plaque PsoriasisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07546214 · 575 enrolled · United States
  14. Oct 5, 2026Phase 3 study suspendedStudy stoppedNCT07265479

Ahead

  1. Aug 2027Primary completion: phase 3 study in Dermatitis, AtopicOrganon · NCT07265479

TargetBeta

AHR →read by rule
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07546214Plaque Psoriasis · United States1CompletedSun Pharmaceutical IndustriesMar 18, 2026575
NCT07265479Dermatitis, Atopic · United States, Canada3Active, not recruitingOrganonAug 2027187
NCT06742957Skin Diseases · United States3CompletedTeva Pharmaceutical IndustriesOct 7, 2025560
NCT05789576Psoriasis · United States4CompletedOrganonJun 30, 202331
NCT05680740Psoriasis · United States4CompletedOrganonMay 18, 202334
NCT05186805Dermatitis, Atopic · United States, Canada2CompletedOrganonAug 24, 202236
NCT05142774Dermatitis, Atopic · United States, Canada3CompletedOrganonFeb 29, 2024728
NCT05172726Plaque Psoriasis · United States, Canada3CompletedOrganonOct 14, 202658
NCT05032859Dermatitis, Atopic · United States, Canada3CompletedOrganonFeb 3, 2023406
NCT05014568Dermatitis, Atopic · United States, Canada3CompletedOrganonMar 30, 2023407
NCT04042103Plaque Psoriasis · United States2CompletedOrganonJan 9, 202021
NCT04053387Psoriasis · United States, Canada3CompletedOrganonApr 6, 2021763
NCT03983980Psoriasis · United States, Canada3CompletedOrganonMay 13, 2020515
NCT03956355Psoriasis · United States, Canada3CompletedOrganonMay 26, 2020510
NCT03202004Psoriasis3WithdrawnGlaxoSmithKlineSep 28, 20180
NCT03201978Psoriasis1WithdrawnGlaxoSmithKlineMay 15, 20180
NCT02564055Dermatitis, Atopic · United States, Canada, Japan2CompletedGlaxoSmithKlineJan 1, 2017247
NCT02564042Psoriasis · United States, Canada, Japan2CompletedGlaxoSmithKlineOct 1, 2016227
NCT02637206Dermatitis, Atopic · Japan1CompletedGlaxoSmithKlineDec 2, 201526
NCT02466152Dermatitis, Atopic · Canada1CompletedGlaxoSmithKlineOct 27, 201511
NCT02411162Dermatitis, Atopic · United States1CompletedGlaxoSmithKlineSep 24, 201515
NCT01984775Psoriasis · United States, Germany1CompletedGlaxoSmithKlineJul 2, 201452
NCT01098734Dermatitis, Atopic · Canada2CompletedWelichem BiotechOct 2010148
NCT01098721Psoriasis2CompletedWelichem BiotechSep 201061
NCT00837551Dermatitis, Atopic · Canada2CompletedWelichem BiotechJun 200836

How it is read

Names in the registry

  • “Tapinarof cream, 1%”, 4 entries
  • “tapinarof cream, 1%”, 4 entries
  • “WBI-1001”, 3 entries
  • “Tapinarof”, 2 entries
  • “GSK2894512 1% Cream”, 2 entries

Codes read as this program: GSK2894512.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.